Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 72Burkitt Lymphoma 43Neoplasm, Residual 18Leukemia 15Recurrence 14Lymphoma, Non-Hodgkin 8Leukemia, Biphenotypic, Acute 8Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoproliferative Disorders 6Lymphatic Diseases 5Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell 4Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia, Lymphoid 4Immunoproliferative Disorders 4Neoplasms 3Blast Crisis 3Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myeloid 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Down Syndrome 2Bites and Stings 2Sarcoma, Myeloid 1Philadelphia-Negative ALL 1Philadelphia Chromosome 1

Interventions

ibrutinib 8fludarabine 8fludarabine phosphate 7Cyclophosphamide 7Busulfan 6Rituximab 5blinatumomab 4Whole-Body Irradiation 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Melphalan 4Methotrexate 3Mesna 3Lenalidomide 3Bendamustine Hydrochloride 3thymoglobulin 2pirtobrutinib 2Vincristine 2Patient Reported Outcome Measures 2Doxorubicin 2Bone Marrow Transplantation 2Biopsy 2Behavior Therapy 2Alemtuzumab 2venetoclax 1tozasertib 1sargramostim 1romiplostim 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Leukemia, Lymphoid × blinatumomab × Clear all
NCT06111625 2023-11-01

Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL

Sichuan University

Phase 2 Recruiting
20 enrolled
Other hematologic neoplasm

Leukemia, Lymphoid

NCT06075238 2023-10-10

Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT

Sichuan University

Phase 2 Not yet recruiting
68 enrolled
Other hematologic neoplasm

Leukemia, Lymphoid

NCT01466179 2017-08-18

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen Research (Munich) GmbH

Phase 2 Completed
225 enrolled 24 charts
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoproliferative Disorders, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01471782 2017-02-08

Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Amgen Research (Munich) GmbH

Phase 1/2 Completed
93 enrolled 21 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡